Effect of sofosbuvir and velpatasvir therapy on clinical outcome in hepatitis C virus patients with decompensated cirrhosis.
Yuki TahataRyotaro SakamoriKazuki MaesakaAkira DoiRyoko YamadaTakahiro KodamaHayato HikitaMasanori MiyazakiYasutoshi NozakiAkira KanekoMasahide OshitaSatoshi TanakaKazuho ImanakaNaoki HiramatsuNaoki MorishitaKazuyoshi OhkawaTakayuki YakushijinMitsuru SakakibaraSadaharu IioYoshinori DoiTomohide TatsumiTetsuo TakeharaPublished in: Hepatology research : the official journal of the Japan Society of Hepatology (2022)
SOF/VEL therapy may suppress the development of decompensated events and improve the prognosis in decompensated cirrhotic patients; however, the incidence of HCC remains prevalent in these patients irrespective of SOF/VEL therapy.